Xilio Therapeutics (XLO) Retained Earnings (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Retained Earnings data on file, last reported at $500.9 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 226.16% year-over-year to $500.9 million; the trailing twelve-month figure through Mar 2026 stood at $500.9 million (up 226.16% YoY), and the FY2025 full-year result was $454.1 million, up 218.32% from the prior year.
• Retained Earnings rose to $500.9 million in Q1 2026, from $454.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $500.9 million in Q1 2026 to a low of -$429.1 million in Q3 2025.
• A 5-year average of -$84.1 million and a median of -$307.9 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 349.98% in 2022 and plunged 196.12% in 2024, its largest moves.
• Tracing XLO's Retained Earnings over 5 years: stood at $354.8 million in 2022, then tumbled by 191.76% to -$325.5 million in 2023, then declined by 17.89% to -$383.8 million in 2024, then surged by 218.32% to $454.1 million in 2025, then gained by 10.31% to $500.9 million in 2026.
• Business Quant data shows XLO's Retained Earnings at $500.9 million in Q1 2026, $454.1 million in Q4 2025, and -$429.1 million in Q3 2025.